Based on these data, the phase 3 PRECISIONS trial is designed to compare the effect of NAC plus standard care in patients with IPF who have the TOLLIP TT genotype, highlighting a personalized medicine approach to treat IPF. The gene discussed is TOLLIP; the disease is idiopathic pulmonary fibrosis.